Veru Enrolls First Patient In Phase 2b PLATEAU Clinical Trial Of Enobosarm, Oral SARM, To Preserve Muscle And Physical Function And To Augment Fat And Weight Loss When Combined With Wegovy

-- The Phase 2b study to assess enobosarm's ability to preserve lean mass, physical function, and bone as well as burn more fat to produce greater quality and quantity of weight loss in older patients with obesity receiving semaglutide --

-- Interim analysis expected in the first quarter calendar year 2027--


-- Final topline clinical data expected in the fourth quarter calendar year 2027--
 

MIAMI, FL, March 09, 2026 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ:VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, today announced that it has enrolled the first patient in its Phase 2b PLATEAU clinical trial of enobosarm, an oral selective androgen receptor modulator (SARM), to preserve muscle and physical function and to augment fat and weight loss when combined with semaglutide (Wegovy®), a Glucagon-like peptide-1 receptor agonist (GLP-1 RA) drug, for potentially higher quality and quantity of weight loss in older patients with obesity.